Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Salbutamol Stories

2013-06-20 08:25:52

Collaboration intended to advance techniques in modification of bronchial smooth muscle SAUSALITO, Calif., June 20, 2013 /PRNewswire/ -- Sanovas, Inc., a leading developer of micro invasive surgical solutions for the Interventional Pulmonary Science, announced today that it has entered into a patent license and joint development agreement with Mayo Clinic to commercialize a significant innovation in the emerging science of bronchial smooth muscle modification. The collaboration is...

2013-01-28 15:47:46

Pollution from forest fires is impacting the health of people with asthma and other chronic obstructive lung diseases, finds a study in Biomed Central's open access journal Environmental Health. This study uses data from pharmacies and dispensaries to measure the increase in drugs needed to alleviate symptoms associated with pollution. Forest fires burn nearly 1000 km2 of trees in British Columbia every year. The Ministry of Environment keeps a close watch on levels of particulate matter...

2012-09-12 11:01:41

Among adults with asthma controlled with low-dose inhaled corticosteroid therapy, the time to treatment failure was not significantly different among patients who received corticosteroid dose adjustment based on physician assessment, a biomarker, or symptom occurrence, according to a study in the September 12 issue of JAMA. Asthma disease activity varies daily, seasonally, and episodically, presumably related to airway inflammation. "Accordingly, asthma management requires periodic dose...

2012-09-06 06:28:02

ALLEGAN, Mich., Sept. 6, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for albuterol sulfate HFA inhalation aerosol, the generic version of ProAir® HFA. The ANDA filing involved contributions from both Perrigo and Catalent Pharma Solutions, Inc., who partnered on the development of this project. (Logo:...

2012-07-18 02:26:18

Primatene® Mist Critical For Millions of Asthmatics Lacking Health Insurance; All Manufacturer's Net Profits from Sales of Primatene® Mist will be Donated to Charity WASHINGTON, July 18, 2012 /PRNewswire-USNewswire/ -- The makers of Primatene® Mist have launched a campaign to put the over-the-counter inhaler back on the market in the United States, after it was banned because it contains a small amount of chlorofluorocarbons (CFCs), leaving millions of asthmatics...

2012-05-14 06:27:07

In the news release, Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD, issued 14-May-2012 by Pearl Therapeutics over PR Newswire, we are advised by the company that the dateline date should read "May 14, 2012" rather than "May 14, 2011" as originally issued inadvertently. The complete, corrected release follows: Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients...

2012-05-14 02:27:37

REDWOOD CITY, Calif., May 14, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA). PT003 and its components, PT001 (GP MDI) and PT005 (FF MDI) are being developed for the...

2012-04-03 02:27:38

Under Economic Strain, More Women Rely on Community Health Centers for their Daily Health Needs SANTA BARBARA, Calif., April 3, 2012 /PRNewswire-USNewswire/ -- In an effort to provide better care to uninsured women across the country, Teva Pharmaceuticals has provided Direct Relief USA with a donation of women's health products valued at $3 million (wholesale). The donation of 5,000 units of ParaGard®, an intrauterine copper contraceptive, will be distributed by Direct Relief to the...

2012-03-19 10:24:55

EAST HANOVER, N.J., March 19, 2012 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide. Arcapta Neohaler is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not...

2011-11-08 07:15:00

WARRINGTON, Pa., Nov. 8, 2011 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that new data supporting AFECTAIR(TM), the Company's newest product candidate, was presented at the American Association for Respiratory Care (AARC) Congress 2011, internationally recognized as the most relevant medical meeting dedicated to advancing the science and practice of respiratory care. AFECTAIR has been developed by Discovery Labs to simplify the delivery of inhaled...